Both: severe, distinctive pulmonary infections. Aerosolized transmission capacity, bioterrorism relevance (esp. anthrax) though most real cases natural.
Background: B. anthracis general biology/virulence/cutaneous form = see Cutaneous Anthrax topic. THIS = inhalational form.
Mechanism: inhale SPORES (contaminated hide/wool occupational, “wool-sorter’s disease” applies here too; historically bioterrorism). Spores → alveoli → alveolar macrophage phagocytosis → MEDIASTINAL/PERIBRONCHIAL LYMPH NODES → germinate. Fundamentally HEMORRHAGIC MEDIASTINITIS+LYMPHADENITIS, NOT true pneumonia (target = mediastinal lymphatic tissue, not lung parenchyma) — explains CXR finding below.
Clinical: BIPHASIC course. Phase 1: nonspecific flu-like prodrome (fever, malaise, myalgia, mild cough), few days. Phase 2: DRAMATIC rapid progression — high fever, severe dyspnea, hemodynamic collapse (toxin overwhelm). WIDENED MEDIASTINUM on CXR/CT = classic distinctive finding (NOT typical pneumonia pattern) — prompt suspicion in right context (occupational exposure). ± hemorrhagic pleural effusion, secondary hemorrhagic meningitis (hematogenous spread). Historical case-fatality ~90% untreated. MOST LETHAL anthrax form even with modern care.
Diagnosis: blood culture positive by phase 2 (large boxcar Gram+ bacilli). PCR, reference lab confirmation if biosecurity concern. Treatment: same principles as systemic anthrax (Cutaneous Anthrax topic) — combo IV antibiotics + ANTITOXIN (raxibacumab/anthrax immune globulin, blocks PA). Requires MORE aggressive/earlier intervention than cutaneous (worse prognosis) — survival depends on treatment before phase 2 fully develops.
Organism: Burkholderia pseudomallei. Gram-negative bacillus. SOIL/WATER SAPROPHYTE, endemic SE Asia + N. Australia, India (esp. southern coastal) increasingly recognized/underdiagnosed. Transmission: SKIN INOCULATION (cuts/abrasions, dominant natural route), INHALATION (dust/aerosolized water, esp. monsoon/typhoon events), rarely ingestion.
Risk factors: DIABETES MELLITUS = DOMINANT risk factor (majority of cases) — parallel to Mucormycosis’s diabetes link (distinct mechanism though). Also: CKD, chronic lung disease, alcohol excess, immunosuppression (dose-dependent).
“THE GREAT MIMICKER”/“Vietnamese time bomb”:
Clinical: Pulmonary = commonest — mild bronchitis to severe necrotizing pneumonia, can MIMIC TB (cavitary upper-lobe pattern) — real diagnostic confusion risk in TB-endemic regions like India. Disseminated (diabetic/immunocompromised more likely): multiple abscesses (liver, spleen, prostate) + septic shock, HIGH mortality even treated.
Diagnosis: Culture = GOLD STANDARD, but growth can be MISTAKEN FOR CONTAMINANT/misidentified by unfamiliar labs — real pitfall in non-endemic/newly-recognizing settings, needs specific clinical suspicion to prompt lab confirmation.
Treatment: PROLONGED, STAGED (mirrors TB logic/duration — intracellular survival, relapse tendency if cut short):
Both: don’t respond to standard empirical “ordinary pneumonia” antibiotics. Both need SPECIFIC clinical suspicion (occupational history-anthrax; diabetes+endemic residence-melioidosis) to trigger correct workup. Both = substantial mortality if suspicion delayed/missed.
Pulmonary anthrax and melioidosis are grouped here as two genuinely severe, distinctive causes of pulmonary infection with real regional/occupational significance and, in anthrax’s case, notable biosecurity relevance — both organisms are capable of aerosolized transmission and have real bioterrorism history/potential, a point worth noting even though the overwhelming majority of real-world cases arise from natural, non-deliberate exposure.
Bacillus anthracis’s general biology, virulence factors (poly-D-glutamate capsule, tripartite exotoxin), and the far more common cutaneous form of disease are covered in full under Cutaneous Anthrax; this section covers the inhalational form specifically, given how dramatically its clinical course and prognosis differ from the cutaneous presentation despite sharing the same organism and toxins.
Inhalational anthrax follows inhaling spores — typically from contaminated animal hides/wool in an occupational setting (“wool-sorter’s disease” applies to this form specifically, not only the cutaneous form, since inhalation of contaminated dust is a real occupational route for wool-industry workers), or, historically, from deliberately weaponized spore preparations. Inhaled spores reach the alveoli, are phagocytosed by alveolar macrophages, and are transported to the mediastinal and peribronchial lymph nodes, where they germinate — critically, the disease is fundamentally a haemorrhagic mediastinitis and lymphadenitis, not a true pneumonia in the conventional sense, since the organism’s primary pathological target is the mediastinal lymphatic tissue rather than the lung parenchyma itself, which is exactly why the chest X-ray finding described below (mediastinal widening rather than a focal pulmonary infiltrate) makes anatomical sense.
Inhalational anthrax classically follows a biphasic course: an initial, nonspecific, flu-like prodrome (fever, malaise, myalgia, mild cough) lasting a few days, followed by a dramatic, rapidly progressive second phase — high fever, severe dyspnoea, and haemodynamic collapse — as the toxin load from the now-germinated, actively toxin-producing bacilli in the mediastinum overwhelms the host. Widened mediastinum on chest X-ray/CT, reflecting the haemorrhagic mediastinal lymphadenitis described above, is the classic, distinctive radiographic finding — genuinely useful precisely because it is not what a typical bacterial pneumonia looks like, and should prompt anthrax suspicion specifically in the right epidemiological context (occupational wool/hide exposure, or, exceedingly rarely, bioterrorism concern). Haemorrhagic pleural effusions and, in a substantial proportion of cases, secondary haemorrhagic meningitis (from haematogenous spread) can complicate the picture. Historically, inhalational anthrax carried a case-fatality approaching 90% without prompt treatment, and remains the most lethal of anthrax’s clinical forms even with modern intensive care and antitoxin.
Blood cultures are typically positive by the time the second, fulminant phase develops (reflecting the systemic toxin/bacteraemic load at that stage), showing the same large, boxcar Gram-positive bacilli covered under Cutaneous Anthrax; PCR and, where biosecurity concern warrants, reference-laboratory confirmation supplement culture. Treatment follows the same principles as systemic anthrax generally (see Cutaneous Anthrax) — combination IV antibiotics plus antitoxin (raxibacumab or anthrax immune globulin, targeting protective antigen to block further toxin entry into cells) — but genuinely requires far more aggressive, earlier intervention than the cutaneous form given inhalational disease’s dramatically worse prognosis, with survival heavily dependent on treatment starting before the fulminant second phase fully develops.
Burkholderia pseudomallei is a Gram-negative bacillus, genuinely notable as a soil and water saprophyte endemic to Southeast Asia and northern Australia (with India, particularly its southern coastal states, increasingly recognized as a genuine, underdiagnosed endemic region rather than a rare imported curiosity) — the organism survives naturally in wet, tropical soil, and human infection follows direct skin inoculation (through cuts/abrasions during contact with contaminated soil/water, the dominant natural route), inhalation (of contaminated dust or aerosolized water, particularly associated with severe weather events like monsoons/typhoons that aerosolize soil-bound organisms), or, rarely, ingestion.
Diabetes mellitus is overwhelmingly the dominant risk factor — a substantial majority of melioidosis cases occur in diabetic patients, mirroring (though through a distinct mechanism) the same diabetes-driven susceptibility pattern covered under Mucormycosis, and other risk factors (chronic kidney disease, chronic lung disease, alcohol excess, immunosuppression) further compound risk in a genuinely dose-dependent way. Melioidosis has earned the nickname “the great mimicker” or “Vietnamese time bomb” for two related reasons worth understanding together: it can present with an enormous range of clinical pictures (from localized skin/soft-tissue infection through pneumonia to disseminated multi-organ abscess formation, genuinely mimicking tuberculosis, staphylococcal sepsis, or several other unrelated infections depending on presentation), and it is capable of prolonged latency — reactivating, sometimes decades after the original exposure, under conditions of subsequent immunocompromise or physiological stress (the “Vietnamese time bomb” reference specifically arose from documented cases of US veterans developing melioidosis years to decades after Vietnam War-era exposure, having carried the organism latently in the interim).
Pulmonary melioidosis is the commonest presentation, ranging from a mild bronchitis to a severe, rapidly progressive necrotizing pneumonia that can radiographically and clinically resemble tuberculosis closely enough to cause real diagnostic confusion (cavitary upper-lobe disease is a genuinely described pattern) — a point worth remembering specifically in a TB-endemic region like India, where melioidosis can be misdiagnosed as TB or vice versa without specific microbiological confirmation. Disseminated melioidosis, more likely in the diabetic/immunocompromised host described above, produces multiple abscesses across organs — liver, spleen, prostate — and septic shock, with a genuinely high mortality even with treatment.
Culture remains the diagnostic gold standard, though the organism’s growth on routine media can be mistaken for a contaminant or misidentified as a different, less concerning Gram-negative rod by laboratories unfamiliar with it — a genuine, real-world diagnostic pitfall in non-endemic or newly-recognizing-endemic settings, where clinical suspicion has to prompt the laboratory to specifically consider and confirm B. pseudomallei rather than dismissing an unusual isolate. Treatment is genuinely prolonged and staged, reflecting the organism’s intracellular survival capacity and propensity for relapse if treatment is cut short: an intensive IV phase (ceftazidime or a carbapenem, typically for at least 2 weeks, longer for severe/disseminated disease) followed by a prolonged oral eradication phase (co-trimoxazole, typically for 3–6 months) — genuinely mirroring, in both logic and duration, the same intensive-then-continuation staged treatment structure covered under Tuberculosis, and for a related underlying reason: incompletely treated melioidosis, like incompletely treated TB, has a real tendency to relapse from surviving intracellular organisms if the prolonged eradication phase is cut short.
Both organisms share genuinely important practical lessons: neither responds reliably to standard first-line empirical antibiotic choices for “ordinary” pneumonia, both require a degree of specific clinical suspicion (occupational/exposure history for anthrax; diabetes plus endemic-region residence/travel for melioidosis) to trigger the correct diagnostic workup, and both carry substantial mortality specifically when that suspicion is delayed or missed.
Personal revision notes, mnemonics and reminders.
